Search

Search Constraints

You searched for: Date 2022 Author/Creator Pfeffer, Marc A.

Search Results

1. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. (18th January 2022)

2. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. (4th January 2022)

3. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF. (15th February 2022)

4. Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. (31st August 2022)

5. Health‐related quality of life outcomes in PARAGON‐HF. (9th December 2022)

6. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Issue 14 (9th September 2022)

7. Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus– A report from the Atherosclerosis Risk in Communities (ARIC) study. (December 2022)

8. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial. (15th August 2022)

9. Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF. (14th February 2022)

10. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. (23rd December 2022)